title: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
abstract: The purpose of this study was to investigate the effect of dose and duration of infusion of recombinant interleukin-2 (IL-2) on toxicity and immunomodulation. In a phase I/II study, IL-2 was administered intravenously (IV) daily for five consecutive days every other week for 4 weeks of treatment to 23 patients with progressive melanoma, renal, colon, or ovarian cancer by one of four regimens: groups I and II received 3 X 10(5) U/m2/d by two-hour or 24-hour infusion, respectively; groups III and IV received 3 X 10(6) U/m2/d by two-hour or 24-hour infusion, respectively. In a subsequent study, six patients (group V) received a single priming cycle of daily IL-2 for five days at 3 X 10(6) U/m2/d in divided 15-minute infusions every eight hours, before undergoing leukapheresis for lymphokine-activated killer (LAK) cell generation. Toxicity was mild with 3 X 10(5) U/m2/d, but severe chills and fever, moderate hypotension (not requiring IV pressors), and weight gain were observed with 3 X 10(6) U/m2/d. Toxicity was also related to the duration of infusion. In group IV (continuous infusion), fluid retention, weight gain, and azotemia were more frequent and severe than in groups III or V, in which the same total dose was administered by two-hour infusion or in three divided 15-minute infusions. IL-2 induced rebound lymphocytosis, which was directly dose-related and significantly higher in group IV (continuous infusion) than in groups III or V. Dramatic increases in the percentage and absolute number of cells expressing the IL-2 receptor were also most pronounced in group IV. With the higher dose of IL-2, LAK cells appeared in the circulation, and natural killer (NK) cytotoxicity was augmented. The results showed that the toxicity and immunomodulation by IL-2 are dose-dependent and are maximal by continuous infusion compared with two-hour or divided every eight hours infusions.
authors.affiliation: Department of Medicine, School of Medicine, University of Washington, Seattle 98195.
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: D J
authors.initials: DJ
authors.lastname: Lee
authors.forename: C G
authors.initials: CG
authors.lastname: Lindgren
authors.forename: L A
authors.initials: LA
authors.lastname: Benz
authors.forename: C
authors.initials: C
authors.lastname: Collins
authors.forename: D
authors.initials: D
authors.lastname: Levitt
authors.forename: A
authors.initials: A
authors.lastname: Fefer
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000276:immunology / Q000633:toxicity; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D013997:Time Factors
chemical_list: D007376:Interleukin-2